Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy).
Pinto
Duane S
DS
Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
Lorenz
David P
DP
Murphy
Sabina A
SA
Marble
Susan J
SJ
DiBattiste
Peter M
PM
Demopoulos
Laura A
LA
Cannon
Christopher P
CP
Gibson
C Michael
CM
D015906:Angioplasty, Balloon, Coronary; D001780:Blood Coagulation Tests / Q000592:standards*; D003327:Coronary Disease / Q000628:therapy; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006470:Hemorrhage / Q000139:chemically induced*; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077466:Tirofiban; D014443:Tyrosine / Q000008:administration & dosage* / Q000031:analogs & derivatives
D005343:Fibrinolytic Agents; D014443:Tyrosine; D006493:Heparin; D000077466:Tirofiban